Sargent Investment Group LLC Sells 498,000 Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD)

Sargent Investment Group LLC lessened its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) by 92.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,500 shares of the company's stock after selling 498,000 shares during the period. Sargent Investment Group LLC's holdings in Lucid Diagnostics were worth $65,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in Lucid Diagnostics during the 4th quarter valued at approximately $98,000. LPL Financial LLC raised its position in Lucid Diagnostics by 29.1% in the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company's stock worth $44,000 after purchasing an additional 12,035 shares during the period. Geode Capital Management LLC raised its position in Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock worth $229,000 after purchasing an additional 65,964 shares during the period. XML Financial LLC purchased a new stake in Lucid Diagnostics in the 1st quarter worth about $266,000. Finally, Lido Advisors LLC grew its stake in Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock worth $115,000 after acquiring an additional 40,000 shares in the last quarter. Institutional investors own 74.01% of the company's stock.

Lucid Diagnostics Stock Down 1.8%

Shares of LUCD opened at $1.12 on Monday. The company has a market capitalization of $121.17 million, a PE ratio of -0.84 and a beta of 1.23. Lucid Diagnostics Inc. has a 52-week low of $0.72 and a 52-week high of $1.80. The company has a 50-day simple moving average of $1.24 and a 200-day simple moving average of $1.24.

Analyst Ratings Changes

Several brokerages have weighed in on LUCD. Cantor Fitzgerald restated an "overweight" rating and issued a $2.00 target price on shares of Lucid Diagnostics in a research note on Thursday, May 15th. Ascendiant Capital Markets lifted their price objective on shares of Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a report on Friday, June 6th. BTIG Research set a $2.00 target price on shares of Lucid Diagnostics in a research report on Tuesday, March 25th. Wall Street Zen lowered shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Needham & Company LLC restated a "buy" rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Wednesday, July 16th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $3.55.

Lucid Diagnostics Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.